Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 5/2017

01-07-2017 | Original Paper

Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees

Authors: N. Zander, I. Schäfer, M. Radtke, A. Jacobi, H. Heigel, M. Augustin

Published in: Archives of Dermatological Research | Issue 5/2017

Login to get access

Abstract

The field of dermatological comorbidity in psoriasis is only passively explored with contradictory results. Objective of this study was to further investigate the complex field of psoriasis and associated skin diseases by identifying skin comorbidity patterns in an extensive cohort of employees in Germany. Retrospective analysis of data deriving from occupational skin cancer screenings was conducted. From 2001 to 2014 German employees between 16 and 70 years from different branches underwent single whole-body screenings by trained dermatologists in their companies. All dermatological findings and need for treatment were documented. Point prevalence rates and their 95% confidence intervals were computed. Logistic regression analysis was performed to calculate odds ratios (OR) of single dermatological diseases to occur together with psoriasis controlled for age and sex. Data from 138,930 persons (56.5% male, mean age 43.2) were evaluated. Psoriasis point prevalence was 2.0%. Of those 20.6% had unmet treatment needs of their disease. Onychomycosis was the most frequent dermatological comorbidity with a prevalence of 7.8%. Regression analysis found rosacea (OR = 1.40, 95% CI 1.13–1.72) and telangiectasia (OR = 1.25, 95% CI 1.10–1.41) to be significantly associated with psoriasis. 17.2% of psoriasis patients had at least one further finding requiring treatment. The highest treatment needs were found for onychomycosis (3.4%), tinea pedis (3.1%), and verruca plantaris (1.0%). It can be concluded that persons with psoriasis are at increased risk to suffer from comorbid skin diseases, which should be considered in treatment regimens. Particular attention should be paid to fungal diseases of the feet.
Literature
1.
Alteras I, Ingberg A, Segal R et al (1986) The incidence of skin manifestations by dermatophytes in patients with psoriasis. Mycopathologia 95(1):37–39CrossRefPubMed
2.
Altunay ZT, Ilkit M, Denli Y (2009) Psöriazisli olgularda tinea pedis ve ayak tirnaği onikomikozu prevalansinin araştirilmasi. Mikrobiyol Bul 43(3):439–447PubMed
3.
Arunachalam M, Dragoni F, Colucci R et al (2014) Non-segmental vitiligo and psoriasis comorbidity—a case-control study in Italian patients. J Eur Acad Dermatol Venereol 28(4):433–437CrossRefPubMed
4.
Augustin M, Glaeske G, Radtke M et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636CrossRefPubMed
5.
Augustin M, Krüger K, Radtke M et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a Multicenter Cross-Sectional Study in Germany. Dermatology 216(4):366–372CrossRefPubMed
6.
Augustin M, Reich K, Glaeske G et al (2010) Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147–151CrossRefPubMed
7.
Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in psoriasis–health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9(10):833–838PubMed
8.
9.
Blome C, Simianer S, Purwins S et al (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159CrossRefPubMed
10.
Boehncke W-H, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343–348CrossRefPubMed
11.
12.
Eisen EA, Picciotto S, Robins JM (2013) Healthy worker effect. In: El-Shaarawi AH, Piegorsch WW (eds) Encyclopedia of environmetrics, 3rd edn. Wiley
13.
Eissing L, Radtke MA, Zander N et al (2016) Barriers to guideline-compliant psoriasis care: analyses and concepts. J Eur Acad Dermatol Venereol 30(4):569–575CrossRefPubMed
14.
15.
Hamnerius N, Berglund J, Faergemann J (2004) Pedal dermatophyte infection in psoriasis. Br J Dermatol 150(6):1125–1128CrossRefPubMed
16.
Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986CrossRefPubMed
17.
Klaassen KMG, Dulak MG, van de Kerkhof PCM et al (2014) The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol 28(5):533–541CrossRefPubMed
18.
Kragballe K, Austad J, Barnes L et al (2006) A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of Psoriasis vulgaris. Br J Dermatol 154(6):1155–1160CrossRefPubMed
19.
Lebwohl MG, Bachelez H, Barker J et al (2014) Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70(5):871–881.e1–30CrossRefPubMed
20.
Leibovici V, Ramot Y, Siam R et al (2014) Prevalence of tinea pedis in psoriasis, compared to atopic dermatitis and normal controls–a prospective study. Mycoses 57(12):754–758CrossRefPubMed
21.
Meyer-Hoffert U (2009) Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp 57(5):345–354CrossRef
22.
Montaudié H, Albert-Sabonnadière C, Acquacalda E et al (2014) Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 28(9):1186–1191CrossRefPubMed
23.
Nast A, Boehncke W-H, Mrowietz U et al (2012) S3—guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 10(Suppl 2):S1–S95CrossRef
24.
25.
Paquet P, Claessens N, Piérard-Franchimont C et al (2005) Effets cutanés indésirables du lithium. Rev Med Liege 60(11):885–887PubMed
26.
Parisi R, Symmons DP, Griffiths CE et al (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol 133(2):377–385CrossRefPubMed
27.
Poljacki M, Begenesić M, Duran V et al (2002) Psorijaza i oboljenja koze autoimunske prirode. Med Pregl (Medicinski pregled) 55(7–8):325–328CrossRef
28.
Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691CrossRefPubMed
29.
Radtke MA, Schafer I, Glaeske G et al (2016) Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. doi:10.​1111/​jdv.​13813
30.
Rapp S, Feldmann S, Exum M et al (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:401–407CrossRefPubMed
31.
Reich A, Hrehorów E, Szepietowski JC (2010) Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 90(3):257–263CrossRefPubMed
32.
Reich K (2012) The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 26(Suppl 2):3–11CrossRefPubMed
33.
Reich K, Krüger K, Mössner R et al (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047CrossRefPubMed
34.
Sawchuk M, Spano F, Loo WJ et al (2012) The coexistence of psoriasis and vitiligo: a review. J Cutan Med Surg 16(5):300–305CrossRefPubMed
35.
Schaefer I, Rustenbach SJ, Zimmer L et al (2008) Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 217(2):169–172CrossRefPubMed
36.
Schäfer I, Rustenbach SJ, Radtke M et al (2011) Epidemiologie der Psoriasis in Deutschland-Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen 73(5):308–313CrossRefPubMed
37.
38.
Schittek B, Paulmann M, Senyurek I et al (2008) The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets 8(3):135–143CrossRefPubMed
39.
Schmid-Ott G, Malewski P, Kreiselmaier I et al (2005) Psychosocial consequences of psoriasis—an empirical study on the burden of skin disease in 3753 patients. Hautarzt 56(5):466–472CrossRefPubMed
40.
Sheth VM, Guo Y, Qureshi AA (2013) Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology 227(4):311–315CrossRefPubMed
41.
Shi VY, Leo M, Hassoun L et al (2015) Role of sebaceous glands in inflammatory dermatoses. J Am Acad Dermatol 73(5):856–863CrossRefPubMed
42.
Ständer S, Schäfer I, Phan NQ et al (2010) Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 221(3):229–235CrossRefPubMed
43.
Szepietowski JC, Reich A, Garlowska E et al (2006) Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 142(10):1279–1284CrossRefPubMed
44.
45.
Yazici A, Akturk AS, Cefle A et al (2014) Rosacea associated with etanercept. Joint Bone Spine 81(3):274–275CrossRefPubMed
46.
Yeung CK, Chan HHL (2004) Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 5(1):3–8CrossRefPubMed
47.
48.
Zhu K-J, Lv Y-M, Yin X-Y et al (2011) Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One 6(11):e23089CrossRefPubMedPubMedCentral
Metadata
Title
Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees
Authors
N. Zander
I. Schäfer
M. Radtke
A. Jacobi
H. Heigel
M. Augustin
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 5/2017
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-017-1741-4

Other articles of this Issue 5/2017

Archives of Dermatological Research 5/2017 Go to the issue

Original Paper

Microscopic and ultrastructural evidences in human skin following calcium hydroxylapatite filler treatment

Original Paper

Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis

Concise Communication

Effects of palmitoyl-KVK-L-ascorbic acid on skin wrinkles and pigmentation

Erratum

Erratum to: Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial–mesenchymal transition in squamous cell carcinoma

Concise Communication

Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study

Original Paper

Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis